Hydroxychloroquine Use and Risk of CKD in Patients with Rheumatoid Arthritis.
Chia-Lin Wu， Chia-Chu Chang， Chew-Teng Kor， Tao-Hsiang Yang， Ping-Fang Chiu， Der-Cherng Tarng， Chih-Cheng Hsu.
Abstract
Background and objectives Hydroxychloroquine is widely used in patients with rheumatoid arthritis. However， large-scale studies examining the long-term effects of hydroxychloroquine on the development of kidney disease in patients with rheumatoid arthritis are lacking. We aimed to assess the long-term association of hydroxychloroquine use with the risk of developing CKD in this population.
Design， setting， participants， & measurements We conducted an observational cohort study for patients with newly diagnosed rheumatoid arthritis who were enrolled prospectively in Taiwan’s National Health Insurance Research Database between January 1， 2000 and December 31， 2013. We used multivariable Cox proportional hazard regression to analyze the association of hydroxychloroquine use with incident CKD.
Results A total of 2619 patients， including 1212 hydroxychloroquine users and 1407 hydroxychloroquine nonusers， were analyzed. Incident CKD was reported in 48 of 1212 hydroxychloroquine users and 121 of 1407 hydroxychloroquine nonusers. The incidence rate of CKD was lower in hydroxychloroquine users than in hydroxychloroquine nonusers (10.3 versus 13.8 per 1000 person-years). After multivariable adjustment， hydroxychloroquine users still had a lower risk of incident CKD (adjusted hazard ratio， 0.64; 95% confidence interval， 0.45 to 0.90; P=0.01) than hydroxychloroquine nonusers. The lower risk of subsequent CKD development was dose dependent and consistent across subgroup analyses.
Conclusions Hydroxychloroquine use in patients with newly diagnosed rheumatoid arthritis is associated with a significantly lower risk of incident CKD compared with in nonusers.
Clin J Am Soc Nephrol. 2018 Apr 16
http://cjasn.asnjournals.org/content/early/2018/04/15/CJN.11781017.abstract
| 
最新消息
